Compare Autozone Inc (AZO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs BIO-TECHNE Corp — how do they compare? Autozone Inc trades at $3,019.81 (market cap $50.27B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Autozone Inc is far larger — about 4.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Autozone Inc pays none. Which is the better fit depends on your goals.
| AZO | TECH | |
|---|---|---|
Market Cap | $50.27B | $11.12B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $71.38 |
52-Week Low | $2.94K | $43.31 |
Enterprise Value | $62.64B | $11.20B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
